Mikhail Blagosklonny: A Review of His Life Achievements

Mikhail Blagosklonny is currently professor of Oncology at the Roswell Park Cancer Institute. He was appointed to this position since 15th April 2009. Prior to this coveted appointed he was a Senior Scientist at the Ordway Research Institute in Albany, New York.

Shortly before he took up this job in the year 2002, he was appointed Associate Professor of Medicine at New York Medical College situated at Valhalla in New York.He is an Editor-in Chief of Oncotarget. He also seats in the journal’s Editorial Board of Cell Death and Differentiation.

He is also an Associate Editor of Cancer Biology and Therapy of the same journal. He doubles up as the Founder Editor and Editor in Chief of Cell Cycle journal.Mikhail Blagosklonny is an alumnus of First Pavlov State Medical University of St Petersburg. He graduated with an M.D. in Internal Medicine and a PhD in Experimental Medicine and Cardiology. He is well known for his role in TOR signalling in aging and cancer.

View Mikhail’s profile in LinkedIn

He is even more renowned for his advocacy of the use of the cancer drug Rapamycin for possible longevity of life. He has done a lot of research on cancer and target cancer therapies. He has done research on Biogerontology (Mechanisms of Aging) and has proposed Rapamycin as an anti-aging drug.

He holds many publications under his name. He has published more than 270 papers. He is recorded as having used more than 25,000 citations. He thus holds an h-index of 83.From the foregoing, it is clear that Mikhail Blagosklonny is an accomplished Physician, Scientist and Professor of Medicine and Oncology.

He has risen through the ranks with various top-notch appointments. He now holds the position of Professor of Oncology at the Roswell Park Cancer Institute. He continues to write more publications having written more than 270 paper hitherto. He is passionate in Bio gerontology and has even proposed use of Rapamycin to elongate life.

Follow Mikhail on Loop

Clay Siegall Looks to the Future of Lymphoma Therapies

Speaking in an interview while representing Seattle Genetics, President and CEO Clay Siegall gave a little insight into what he feels is the future of both his company, and lymphoma treatment in general. In particular, President Siegall spoke about the role of the FDA in the future of his company, as their regulations have a direct impact on the progress his researchers can make.

In addition to speaking about the FDA, President Siegall also talked about his companies plans moving forward. As it currently stands, Presdient Siegall and Seattle Genetics are pursuing several different projects that all relate to various forms of lymphoma. In addition to its primary submissions to the FDA, President Siegall is also excited by several stage 3 clinical trials that are currently underway within the company.

 

Given the importance of these trials for both the future of Seattle Genetics and lymphoma treatment options as a whole, it will be interesting to see how these trials conclude and what their ramifications will be. For his part, President Siegall has been adamant in collecting as much data as possible on these trials, so that they can then be published for others to take a look at sometime in the future. In President Siegall’s mind, transparency is of critical importance to the success of Seattle Genetics.

In addition to a pronounced focus on transparency, Seattle Genetics has also proven to be interested in working with others. President Siegall pointed to recent efforts in researching immunogenic cell death as proof of their collaborative efforts.

What the future holds in store for President Siegall and Seattle Genetics is still unclear, but it remains hopeful. As the pharmaceutical company expands its knowledge-base and researching capabilities, it is sure to continue growing in prominence within the pharmaceutical industry.

Clay Siegall leads Seattle Genetics in unveiling 12 new cancer treatment drugs

Seattle Genetics is a company that engages in commercialization and development of antibody drugs that fight cancer. Their main product sold across commercial stores has the label Adcetris. The product has been approved by the Health Association and the U.S. Food and Drug Association in both Canada and the U.S. Adcetris is a drug that focuses on producing antibodies that conjugate cancer cells hence destroying them. The company was found by H. Perry Fell and Clay B. Siegall on July 1997. The company is today headquartered at Bothell, WA.

Dr. Siegall has played the lead role in Seattle genetics success. He graduated with a Ph.D. in Genetics received from George Washington University. He holds a Bachelor of Science in Zoology from Maryland University. Before becoming the CEO of the Seattle Genetics company, he worked at several research institutes. He dedicated a large part of his life between 1988 and 1997 to cancer and research institutions. Seattle Genetics has grown to become a popular biotech company. It focuses on commercialization, development and innovation of cancer patients.

Seattle Genetics today has a plan to expand the use of its cancer drug and increase its shelf with new drugs. The company wants to increase the number of employees so as to achieve its vision quickly and efficiently. According to the company CEO Dr. Clay Siegall, the company has tried its first drug in about 70 different occasions used to treat cancer cells. Results from the drug have been amazing, the drug has been used to fight lymphomas and managed to give the company revenues worth $226 million in 2015. The company has since partnered with pharmaceuticals that aid in selling drugs in Canada and the US. Its partnership with Takeda Pharmaceuticals has seen Seattle increase its market for drug sales.

Dr. Clay Siegall is behind the massive success of the company. Through his efforts, the company has managed to secure more than $675 million in fundraising. Siegall’s main drive is to discover the cure for the disease that claims lives of thousands of people every year. His passion has seen him help the company in terms of private and public fundraising.